A face-off in the US between two different strengths of interchangeable Humira (adalimumab) biosimilars could be on the cards for 1 July 2023, after Alvotech settled all of its legal disputes with originator AbbVie, gaining a launch date that matches that of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) version.
While Cyltezo has already been approved by the US Food and Drug Administration – with the lower-strength 50mg/ml adalimumab biosimilar also granted an interchangeability designation last year (Also see "First Interchangeable Humira Biosimilar Approved In US" - Generics Bulletin, 18 October, 2021